Navigation Links
A drug-dispensing contact lens

Taking eye drops multiple times a day can be difficult for patients to do, and because of blinking and tearing, as little as 1 to 7 percent of the dose is actually absorbed by the eye. Now, researchers led by Daniel Kohane, MD, PhD, director of the Laboratory for Biomaterials and Drug Delivery at Children's Hospital Boston, have developed special contact lenses that can gradually dispense a constant amount of medication to the eye, at adjustable rates. They describe their prototype lens in the July issue of Investigative Ophthalmology and Visual Science.

Although other groups have developed drug-releasing contact lenses, none have been able to achieve a constant, steady release of substantial amounts of drug; typically, a burst of drug is delivered in the first few hours, followed by rapidly dwindling amounts that are too low to be therapeutic. Kohane, collaborator Joseph Ciolino, MD, of the Massachusetts Eye and Ear Infirmary, and colleagues at the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT) created a two-layer contact lens with an inner drug-bearing biodegradable polymer film known as PLGA. Both PLGA and pHEMA (used for the coating) have been well studied and are already approved for ocular use by the Food and Drug Administration.

In laboratory testing, the prototype lenses dispensed ciprofloxacin (an antibiotic often used in eyedrops) for 30 days, the longest duration for which contact lenses are currently approved by the FDA; in some tests, the lenses continued releasing drug for up to 100 days. The amounts dispensed were sufficient to kill pathogens in a laboratory assay.

Kohane and Ciolino see applications in conditions such as glaucoma and dry-eye which require frequent daily eye drops. They have begun to test the lens in animals and plan to begin human testing as soon as possible. The technology recently won the Life Sciences track in MIT's 100K Entrepreneurship Competition.


Contact: Jamie Newton
Children's Hospital Boston

Related biology technology :

1. BioMS Medical to present at BioContact 2007
2. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
3. Dragon to Present at BioContact Quebec 2008
4. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
5. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
Post Your Comments:
Related Image:
A drug-dispensing contact lens
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of ... has promoted Melanie Aregger to serve as Chief Operating Officer. , Having ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
(Date:11/24/2015)... 24, 2015 HemoShear Therapeutics, LLC, a ... for metabolic disorders, announced today the appointment of ... of Directors (BOD). Mr. Watkins is the former ... Sciences (HGS), and also served as the chairman ... Powers , Chairman and CEO of HemoShear Therapeutics. ...
(Date:11/24/2015)... YORK , Nov. 24, 2015 According to ... than in 2005. This is something that many doctors, scientists, ... time. One questions remains: with fewer PSA tests being done, ... ? Dr. David Samadi, "Despite the ... the disease remains the second leading cancer cause of death ...
(Date:11/23/2015)... ... November 23, 2015 , ... ... development of its Nexera UC Unified Chromatography system. The award from R&D magazine ... new products of the year in the analytical and testing category. R&D Magazine ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):